You’ve seen the labels: “10 mg per gummy.” Looks clean. Sounds simple. But most manufacturers struggle to make every single gummy in a batch actually identical. The dose-to-dose spread can be wide enough to land a brand in regulatory hot water.
When a consumer bites into a gummy, they trust that the dose is exactly what’s printed on the package. If one piece delivers 12 mg and another delivers 8 mg, that’s not just a quality hiccup; it’s a breach of trust. And in our industry, trust is everything.
The manufacturing reality that rarely gets discussed is homogeneity: the engineering challenge of getting the active ingredient evenly distributed throughout every single gummy in the tray.
Why Emulsion Quality Matters More Than You Think
Delta-9 THC is an oil. Gummy base is mostly water. Getting oil to stay evenly suspended in water isn’t as simple as stirring harder. The oil droplets need to be broken down to microscopic size, ideally under 20 microns. If the droplets are too large, they’ll float to the top during the depositing process. The first gummy in the row might test high, the last one low.
I’ve seen batches where the potency variance hit 15% or more simply because the emulsion wasn’t tight enough. That’s not acceptable under cGMP standards, and it’s a risk no brand should take.
The Pour Time Window Nobody Monitors
Once you mix the THC emulsion into the hot gummy slurry, the clock starts ticking. The mixture begins to stratify. If your depositing line takes 20 minutes to fill a batch of molds, the concentration in the holding tank will shift during that time.
At KorNutra, we run hold-time studies for every Delta-9 gummy batch. We test potency at regular intervals: T=0, T=5, T=10, and T=15 minutes during a simulated fill. If the variation exceeds 3%, we go back and adjust the emulsifier blend or reduce batch size. That’s the kind of rigor that keeps labels honest.
Infusion Is Not Encapsulation
A common mistake I see in newer facilities is treating gummy production like large-scale capsule filling. But they’re fundamentally different processes. In capsule filling, you blend the active with a powder and fill. Simple. In gummies, the active is dissolved or dispersed into a hot liquid matrix. There is no encapsulation step. The gummy is the delivery vehicle.
This changes how you think about everything: temperature, shear rate, cooling profile, even the shape of the mold. A tall, narrow gummy shape is more prone to sedimentation than a flat, wide one. I’ve watched operators ignore mold geometry, then scratch their heads when potency variance hits 20%. The details matter.
The cGMP Testing Protocol That Works
Under 21 CFR Part 111, the cGMP rule for dietary supplements, you’re required to establish finished product specifications for identity, purity, strength, and composition, and to verify finished batches against them. But one test per 3,000 gummies won’t cut it. You need stratified sampling across the entire fill process.
A strong homogeneity protocol includes:
- In-process sampling: grab samples every five minutes during depositing
- Final batch release: test ten gummies from different locations: top, middle, and bottom of the tray, across the cooling belt
- Stability testing: re-test at one, three, and six months to confirm the emulsion doesn’t break over time
This multi-tier approach catches problems early and ensures consistency throughout the shelf life.
Why Uniformity Is a Compliance Battleground
Without making any medical claims, I can tell you this: regulatory bodies don’t look kindly on a batch where gummies from the same run vary by double digits. That’s a misbranding risk. And if a consumer ends up with a “hot” gummy, one carrying more THC than the label states, due to poor homogeneity, the manufacturer bears full responsibility.
The industry focus has long been on staying under the 0.3% Delta-9 by dry weight limit that defines hemp. But uniformity is the real compliance mountain. Too few operators treat gummy homogeneity as a process validation exercise. At KorNutra, we see it as the defining characteristic of a professional manufacturing operation.
What the Move to Total THC Means for Testing
P.L. 119-37, enacted in November 2025, redefines hemp as cannabis with a total THC concentration below 0.3% on a dry weight basis, effective November 12, 2026. THCA, the acidic precursor that converts to delta-9 THC under heat, now counts toward that cap. Under the old standard, an extract could carry THCA while a lab reported only delta-9 and the batch still cleared; after November, manufacturers will need to measure THCA alongside delta-9 and control decarboxylation during extraction, because the two together set the compliance number. A narrower margin also raises the stakes for dose-to-dose uniformity, because a “hot” gummy pushes the total THC reading higher too. Hold-time studies and stratified sampling are not optional extras. They are how a brand stays on the right side of a redefined limit.
Engineering Discipline Is the Difference
The difference between “good enough” and “cGMP excellent” comes down to engineering discipline. The former uses a pre-made extract, stirs it into a pot, and pours. The latter treats every batch as a unique emulsion challenge: pre-qualifying the emulsifier system, validating the hold-time, and tracking potency CV for every production run.
That’s the level of rigor your brand deserves. And it’s the only way to ensure that the Delta-9 gummy a consumer pulls from the bottom of the bag delivers exactly what your label promises every single time.
This article is for informational purposes only and does not constitute medical or legal advice. KorNutra complies with all applicable federal and state regulations for hemp-derived products.